Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic by McGregor, CG, Adams, A, Sadler, R, Arancibia-Cárcamo, CV, Palmer, R, Ambrose, T, Brain, O, Walsh, A, Klenerman, P, Travis, SP, Croft, NM, Lindsay, JO, Satsangi, J

Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease by Gonçalves Serra, E, Schwerd, T, Moutsianas, L, Cavounidis, A, Fachal, L, Pandey, S, Kammermeier, J, Croft, NM, Posovszky, C, Rodrigues, A, Russell, RK, Barakat, F, Auth, MKH, Heuschkel, R, Zilbauer, M, Fyderek, K, Braegger, C, Travis, SP, Satsangi, J, Parkes, M, Thapar, N, Ferry, H, Matte, JC, Gilmour, KC, Wedrychowicz, A, Sullivan, P, Moore, C, Sambrook, J, Ouwehand, W, Roberts, D, Danesh, J, Baeumler, TA, Fulga, TA, Karaminejadranjbar, M, Ahmed, A, Wilson, R, Barrett, JC, Elkadri, A, Griffiths, AM, COLORS in IBD group investigators, Oxford IBD cohort study investigators, INTERVAL Study, Swiss IBD cohort investigators, UK IBD Genetics Consortium, NIDDK IBD Genetics Consortium, Snapper, SB, Shah, N, Muise, AM, Wilson, DC, Et al